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Abstract
Background: A central feature of Alzheimer's disease is the cleavage of the amyloid precursor protein (APP) to form 
beta-amyloid peptide (Aβ) by the β-secretase and γ-secretase enzymes. Although this has been shown to occur after 
endocytosis of APP from the cell surface, the exact compartments of APP processing are not well defined. We have 
previously demonstrated that APP and γ-secretase proteins and activity are highly enriched in purified rat liver 
lysosomes. In order to examine the lysosomal distribution and trafficking of APP in cultured cells, we generated 
constructs containing APP fused to a C-terminal fluorescent protein tag and N-terminal HA-epitope tag. These were 
co-transfected with a panel of fluorescent-protein tagged compartment markers.
Results: Here we demonstrate using laser-scanning confocal microscopy that although APP is present throughout the 
endosomal/lysosomal system in transfected Cos7 and neuronal SN56 cell lines as well as in immunostained cultured 
mouse neurons, it is enriched in the lysosome. We also show that the Swedish and London mutations reduce the 
amount of APP in the lysosome. Surprisingly, in addition to its expected trafficking from the cell surface to the early and 
then late endosomes, we find that cell-surface labelled APP is transported rapidly and directly from the cell surface to 
lysosomes in both Cos7 and SN56 cells. This rapid transit to the lysosome is blocked by the presence of either the 
London or Swedish mutations.
Conclusions: These results demonstrate the presence of a novel, rapid and specific transport pathway from the cell 
surface to the lysosomes. This suggests that regulation of lysosomal traffic could regulate APP processing and that the 
lysosome could play a central role in the pathophysiology of Alzheimer's disease.
Background
One of the pathological hallmarks of Alzheimer's disease
(AD) is the production and cerebral deposition of the β-
amyloid (Aβ) peptides. Aβ peptides are generated by the
sequential proteolysis of the Amyloid Precursor Protein
(APP). β-Secretase (BACE) performs the first cleavage of
APP at an extracellular/luminal 'β-site' which removes the
bulky extracellular domain of APP [1,2]. This initial cleav-
age is followed by a second cleavage at a 'γ-site' within the
transmembrane domain of APP by γ-secretase to yield
the 40-42 amino acid Aβ peptide [3,4].
APP is a type 1 transmembrane protein that is trans-
ported to the cell surface where it undergoes rapid endo-
cytosis based upon a C-terminal tyrosine-based sorting
signal. APP then either recycles back to the cell surface or
is targeted to late endosomes/lysosomes [5-10]. Many
lines of evidence suggest that APP processing by
secretases occurs in the endosomal/lysosomal system
(reviewed in [11]). Aβ production is reduced by blocking
the internalization of cell surface APP [12,13], and block-
ing the acidification of the endosomal-lysosomal system
[8,14,15]. Furthermore, amyloidogenic APP fragments
accumulate in lysosomes after treatment with protease
inhibitors and in presenilin-1 knockout cells lacking γ-
secretase activity [15-18]. However, there is also evidence
suggesting that APP processing may occur in other com-
partments and the site of these critical biochemical
events remains controversial [18-21].
The Swedish mutation causes early onset Familial AD
by increasing the rate of β-cleavage by 5-10 fold [22] and
is proposed to alter the trafficking of APP. This mutation
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partly disrupts polarized sorting of secreted APP [23] and
appears to undergo β-cleavage during transit to the cell
surface [24,25]. In contrast, the "London" mutant involves
a missense mutations at codon 717 and increases the rela-
tive amount of the more toxic Áβ42 produced by γ-cleav-
age [26], but is not proposed to alter trafficking.
Previously, we provided evidence that the lysosome
might be an important site of Aβ production [27,28]. In
the present study, we demonstrate that APP is enriched in
the lysosome compared to early and late endosomes in
transfected cultured cells and immunostained mouse
neurons and that cell surface APP is transported rapidly
and directly to the lysosomal compartment. This rapid
lysosomal transport is blocked by the presence of the
Swedish and London mutations. Taken together, our
experiments demonstrate a novel highly selective rapid
and direct sorting pathway from the cell surface to the
lysosome.
Results
Localization of FL-APP and βAPP in the endosomal/
lysosomal compartment
We first examined the distribution of fluorescent protein
tagged APP in non-neuronal cells to determine if would
indeed be enriched in lysosomes and other endocytic
compartments. To eliminate the possibility of interfer-
ence from large (likely non-secretase related) cleavage
p r od u cts  o f  AP P  t h a t  w e  a n d  o t h e r s  h a v e  o bs e rv ed  i n
purified lysosomes (data not shown) and poorly defined
sorting signals in the luminal domain of APP [23,25,29],
we generated a shorter APP constructs beginning 12
amino acids upstream of the β-cleavage site, referred to as
βAPP (Figure 1). We then co-transfected Cos7 cells with
either full-length APP-YFP or -CFP (FL-APP) or β APP-
CFP along with compartment markers that label early
endosomes (Rab5), late endosomes/lysosomes (Rab7) and
lysosomes (LAMP1). We found that FL-APP and βAPP
were colocalized to the same intracellular compartments
in transfected Cos7 cells (Figure 2A). Moreover, both
APP constructs exhibited extensive colocalization with
Rab5, Rab7 and Lamp1 (Figure 2B and 2C). Thus the
truncation of the N-terminus of APP did not appear to
alter the intracellular trafficking of βAPP.
APP is present in the endosomal/lysosome system in neural 
cells and neurons
To examine APP distribution in neural cells, we adopted
the SN56 cell line. These cells are a hybrid cell line gener-
ated by fusing dissociated embryonic mouse septal neu-
rons with N18TG2 neuroblastoma cells. SN56 cells
possess neuronal morphology and cholinergic phenotype
when differentiated and express APP [30-32].
In order to compare the levels of APP within various
compartments of the endosomal/lysosomal system, we
set out to quantitate the relative amounts of APP colocal-
ized with organellar compartment markers. Colocaliza-
tion analysis requires the setting of brightness intensity
threshold to determine the level of intensity that is con-
sidered 'positive' for each channel and separating it from
'background' expression. This can then be quantified by
counting the pixels (or the percentage of pixels) that are
positive for both fluorescent labels. The process of
thresholding images is inherently problematic because it
requires the arbitrary determination of the level of
expression is considered significant or positive. Further-
more the brightness of signals in fluorescence images is
highly dependant on numerous variables that are difficult
to control such as variations in cell-to-cell protein expres-
sion, fluorophore brightness, and image acquisition. To
circumvent these problems, we adopted a strategy
described by Hutcheon et al [33] (also discussed in
[34,35]), which sets thresholds based on a fixed percent-
age of the brightest pixels in an image. This allows for the
identification of positive pixels that is unbiased (it does
not require the judgment of the observer on an image to
image basis) and is relatively unaffected by parameters of
image acquisition or the level of protein expression. This
strategy assumes that the most important site of a protein
will have the largest amount of the protein and therefore
brightest signal. This strategy also improves sub-cellular
organelle identification, as proteins that are considered to
be markers of distinct compartments are often present at
lower levels in other compartments. In this study, we set
thresholds to identify the brightest 2% of pixels in each
image. This level was determined empirically to consis-
tently identify APP in punctuate organelle-like patterns.
An example of this analysis is shown in Figure 3 which
demonstrates the colocalization of APP and LAMP1 in
SN56 cells (Figure 3A-B) transfected with βAPP-CFP
(green) and LAMP1 or Cox8 compartment markers
tagged wit h mRFP (red), or mouse neur ons imm unos-
tained with APP (green) and LAMP1 (red) antibodies
(Figure 3C). The merged green-red image shows clear
colocalization of APP and LAMP1 (but not Cox8) in yel-
low, and histograms of the intensities of the green and red
channel are shown. The brightest 2% of pixels in the
green channel was selected as a threshold intensity (the
region on the histogram to the right of the yellow dotted
Figure 1 Overview of Constructs. Shaded region denotes the trans-
membrane domain. Beta-, alpha- and gamma symbols denote 
secretase cleavage sites. Swedish and London mutations are shown. SS 
- signal sequence; HA- HA epitope tag.
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line) that also fall within the brightest 2% of red pixels
(the bound box in the upper right corner of the histo-
gram). These colocalized pixels are identified in a colo-
calization channel (white) and the percentage of the
selected green pixels that are also red is determined as the
percent colocalized. Note that the absolute intensity of
the brightness threshold varies slightly from image to
image, although the portion of the pixels remains the
same. In this figure 49% of threshholded βAPP-CFP is
colocalized with LAMP1, whereas only 4% of βAPP-CFP
is colocalized with Cox8 (Figure 3A and 3B). Similarly,
54% of APP is colocalized with LAMP1 in the selected
immunostained mouse neuron (Figure 3C).
Examining APP colocalization with endosomal/lyso-
somal compartment markers in transfected SN56 cells
(Figure 4), we find that subcellular distribution of βAPP-
CFP in neuronal SN56 cells was similar to that found in
Cos7 cells. We found that βAPP was extensively colocal-
ized with markers of early endosomes (Rab5), late endo-
some/lysosomes (Rab7), late endosomes (Rab9), and
lysosomes (LAMP1) but not mitochondria (Cox8) (Figure
4A). Colocalization analysis was preformed (as described
above) to generate images showing the colocalization of
the brightest 2% of pixels (shown in white). Quantifica-
tion of the brightest 2% of pixels revealed that the extent
of colocalization of intracellular protein βAPP with Rab5,
Rab7, Rab9 and LAMP1 was 35 ± 1.4%, 37 ± 1.4%, 36 ±
1.4%, and 52 ± 3%, respectively (Figure 4B). A 3D image
stack of APP colocalization with LAMP1 in an SN56 cell
is shown in Additional file 1, Supplemental movie S1. The
relatively high levels of colocalization of βAPP observed
in each compartment likely reflects the expected transit
of APP through these compartments. Cox8, a mitochon-
drial marker, exhibits essentially no colocalization (3.4 ±
0.4%) with βAPP. Moreover, βAPP was significantly
enriched in the lysosome compared to the other intracel-
lular compartments (p < 0.05).
To confirm that this colocalization was not due to over-
expression of APP, we examined the distribution of
endogenously expressed APP in cultured mouse primary
cortical neurons immunostained with antibodies that
recognize the C-terminal of APP along with Rab5, Rab9
and LAMP1. Similar to our findings in SN56 cells, endog-
enous APP was extensively colocalized with markers of
Figure 2 APP is preferential expressed in the lysosome in Cos7 cells. Cos7 cells were transiently co-transfected with the fluorescent -tagged APP 
and compartment marker proteins and imaged using laser scanning confocal microscopy. A. Cos7 cells were transiently co-transfected with βAPP-
CFP (green) and the full-length APP-YFP (FL-APP) (red). B. Cos7 cells transiently co-transfected with βAPP-CFP or YFP (green) constructs along with 
fluorescent-tagged compartment markers (red) C. Cos7 cells were transiently co-transfected with βAPP-CFP (green) a constructs along with compart-
ment markers as indicated (red). Scale Bar = 10 microns.
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the early endosomal (Rab5), late endosomal (Rab9) and
lysosomal (LAMP1) compartments (Figure 5). Quantifi-
cation of images revealed that the extent of colocalization
of endogenous APP protein with Rab5, Rab9 and LAMP1
was 28 ± 1.3%, 31 ± 1.9%, and 42 ± 1.3% respectively (Fig-
ure 5B). A 3D image stack of APP colocalization with
LAMP1 in a mouse neuron is shown in Additional file 2,
Supplemental movie S2. As with the transfected cells,
endogenous APP was significantly enriched in the lyso-
somal compartment (p < 0.05) indicating that the fluores-
cently-protein tagged proteins expressed in SN56 cells
exhibited a subcellular localization pattern that mirrors
that of the endogenous protein.
Effect of Swedish and London mutations on the subcellular 
localization of APP
Since both the Swedish and London mutations were pre-
viously demonstrated to alter Aβ production and might
be associated with altered APP trafficking [14,25], we
introduced each of these mutations into separate βAPP-
CFP construct and examined the steady state colocaliza-
tion of the resulting mutants with Rab5, Rab9 and
LAMP1. We found that neither the London nor the
Swedish mutation altered the relative colocalization of
βAPP with Rab5 when compared to wild-type βAPP (Fig-
ure 6A). However , we found that the London mutation
reduced the extent of βAPP localization to both the late
endosomal (Rab9) and lysosomal (LAMP1) compart-
ments (Figure 6B and 6C). In contrast, while the Swedish
mutation did not affect the extent of βAPP colocalization
with Rab9, it significantly reduced βAPP localized to the
lysosome.
Cell surface βAPP internalization to lysosomes
The high levels of APP in the lysosome could be the result
of rapid trafficked to this compartment. Therefore, we
examined the trafficking of wild-type βAPP to LAMP-1
positive lysosomes by imaging live Cos7 cells transfected
with LAMP1-mRFP with and without either HA-tagged
APP (HA-APP-wt-CFP) or βAPP (HA-βAPP-wt-CFP).
Co-transfection of cells was confirmed by observing the
fluorescent protein tags. Subsequently, AlexaFluor 647
conjugated HA antibody was added to confocal dishes
and the internalization of cell surface antibody-labeled
Figure 3 Quantitation of APP enrichment in transfected cells and primary neurons. SN56 cells (A-B) were transfected with transfected with APP-
CFP (green channel) and either LAMP1-mRFP or Cox8-mRFP (red channel) and imaged by confocal microscopy. Mouse neurons (C) were immun-
stained with Anti-C-terminal APP (green channel) and Anti-LAMP1 (red channel). The co-localization of the green and red channels can be view qual-
itatively in the yellow (merge) images and the histograms of these images are shown. To quantify colocalization, the brightest 2% of green (to the 
right of the dotted yellow line) and red pixels (above the yellow solid line on the histograms) is selected. The colocalized pixels are indicated in white 
in the Colocalized Pixels panels.
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APP protein was imaged. We expected to observe only
low levels of APP and βAPP with LAMP1 within 15-30
min following the labeling of cell surface APP protein
with the fluorescent antibody. However, we found that
both wild-type FL-APP and βAPP exhibited extensive
colocalization at early time points (5-10 min) in LAMP1
positive vesicular structures that were found in close jux-
taposition with the plasma membrane (Figure 7A and 7B,
Additional file 3, Supplemental movie S3 and Additional
file 4, Supplemental movie S4). However, the uptake of
AlexaFluor-labeled HA antibody was not non-specific as
no uptake was observed in cells lacking HA-tagged APP
constructs but containing LAMP1-mRFP alone (Figure
7C). The results suggested that APP was rapidly localiz-
ing to lysosomes immediately following endocytosis.
APP transport to the lysosome is both rapid and selective
To further examine the lysosomal transport of cell surface
APP protein, we established the time course of colocal-
ization of surfaced-labeled βAPP-wt-CFP with early
endosomes (Rab5), late endosomes (Rab9) and lysosomes
(LAMP1) in SN56 cells. As a control, the non-specific
uptake of dextran to these compartments was also exam-
ined. Figure 8A shows representative images of the inter-
Figure 4 APP is Enriched in the Lysosome in Neuronal SN56 cells. 
SN56 cells were transiently co-transfected with fluorescent-tagged 
APP and compartment marker proteins and imaged using laser scan-
ning confocal microscopy. A. SN56 cells were transiently co-transfect-
ed with the βAPP-CFP (shown in green) constructs along with 
compartment markers (red) as indicated demonstrating preferential 
co-localization of βAPP with lysosomal marker LAMP1. Colocalized pix-
els were identified as in figure 3 and displayed in the white colocaliza-
tion channel. Scale Bar = 10 microns. B. The colocalization of the 
brightest 2% of pixels of APP and compartment markers was quantitat-
ed by Imaris software. Values are expressed as the mean ± SEM for a 
minimum of 50 cells each for Rab5, Rab7, Rab9 and LAMP1, and 20 cells 
for Cox8, drawn from at least 4 independent transfections. * indicates 
statistically significant difference from all other compartment markers 
(p < 0.05). ** indicates compartment markers that are statistically differ-
ent from LAMP1 and Cox8, but not different from each other each oth-
er (p < 0.05).
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Figure 5 APP is enriched in the lysosome in cultured mouse neu-
rons. A. Cultured mouse neurons were fixed and immunostained with 
antibodies against APP (green) or compartment markers (red) and nu-
clei were counterstained with Hoechst dye (blue). Images were ac-
quired using laser scanning confocal microscopy demonstrating the 
green, red and merged image channels. An additional channel was 
generated showing the where the brightest 2% of red and green pixels 
are colocalized (See Figure 3). Scale bar = 5 microns. B. Quantitation of 
colocalization of the brightest 2% of pixels of APP and compartment 
makers. Each bar represents with mean ± SEM of at least 3 indepen-
dent immunostaining experiments, imaging total of at least 25 cells. * 
indicates the LAMP1 staining is significantly different from Rab5 or 
Rab9 (P < 0.05).
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nalization of AlexFluor 647 anti-HA antibody and
fluorescent dextan to LAMP1-mRFP-labeled lysosomes.
In these images, it is possible to see the anti-HA signal
clearly colocalized with LAMP1 at 5 minutes, but dextran
only begins to show only minor colocalization at 15 min-
ues, with better colocalization present only at the 60 min-
ute time point. To quantitiate this data, we determined
the percent colocalization of fluorescent (anti-HA or dex-
tran) signal with compartment markers at each time
point, and these results were plotted over time (Figure
8B). As expected, we found that βAPP-wt-CFP was inter-
nalized to Rab5- compartment within the first 5-10 min-
utes and only then appears in Rab9-positive
compartments at about 15 minutes. However, we
observed colocalization of fluorescent HA-antibody
labeled βAPP-wt-CFP with LAMP1 at the earliest time
points (5, 10 min), when we did not observe detectable
colocalization between dextran and LAMP1. βAPP-wt-
CFP colocalization with LAMP1 was maximal within 5-
10 min of fluorescent HA-antibody labeling, whereas the
extent of colocalization with the early (Rab5) and late
(Rab9) markers was delayed and was linear over the time
period tested, behaving as would be expected for a pro-
tein which was first transported to the early endosome,
and then to the late endosome. Taken together, the data
suggest that while cell surface APP was internalized to the
Rab5 compartment, and then transited to the Rab9 com-
partment as predicted, a large fraction of cell surface APP
was rapidly and directly internalized to lysosomes,
bypassing endosomal compartments.
Effect of London and Swedish mutations on the rate of APP 
trafficking to lysosomes
Given the observation that both the London and Swedish
mutations altered the extent of APP localization to lyso-
somes, we compared the time course for mutant and
wild-type APP colocalization with early endosomal, late
endosomal and lysosomal markers. We found that Lon-
don and Swedish βAPP exhibited increased colocaliza-
tion with Rab5 at 10 min. when compared to wild-type
βAPP. At 30 minutes, APP-London colocalization with
Rab5 was significantly greater that wt-APP and at 45 min-
utes APP-London colocalization with Rab5 was signifi-
cantly greater than both APP-Swedish and APP-wt.
However, the localization of London, Swedish and wild-
type βAPP in the early endosome was indistinguishable at
60 min (Figure 9A). The maximal extent of Swedish βAPP
colocalization with Rab9 was substantially increased
when compared to either London βAPP or wild-type
βAPP suggesting that the Swedish βAPP transited more
effectively to late endosomes (Figure 9B). The time course
for London βAPP colocalization in late endosomes was
virtually indistinguishable from wild-type βAPP. How-
ever, unlike what was observed for wild-type βAPP, Lon-
don and Swedish βAPP did not rapidly colocalize with
LAMP1 in lysosomes (Figure 9C) and the appearance of
either mutant APP to within this compartment was
delayed. While, London βAPP showed reduced transport
to the lysosome when compared to wild-type, the transit
of Swedish βAPP to the lysosome was accelerated at 30
Figure 6 London and Swedish Mutations reduce APP levels in 
late endosomal and lysosomal compartments. SN56 cells were 
transiently co-transfected with the βAPP-CFP construct with or with-
out the London or the Swedish mutant along with compartment 
markers. Representative fixed cells were imaged using laser-scanning 
confocal microscopy. The colocalization of the brightest 2% of pixels of 
APP mutants with Rab5 (A), Rab9 (B) and LAMP1 (C) was quantitated 
using Imaris software. Values are expressed as the mean ± SEM for a 
minimum of 50 cells drawn from at least 4 independent transfections. 
* indicates statistical difference from wild type and all other compart-
ment markers (p < 0.05). ** indicates compartment markers that are 
statistically different from wild type (p < 0.05) but not from each other. 
Scale bar = 10 microns.
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and 45 min when compared to London βAPP, which was
consistent with its increased transport to the late endo-
somes. Taken together, these data indicated that the
kinetics of both London and Swedish βAPP localization
to lysosomes was altered when compared with wild-type
βAPP. This suggested that distinct intracellular trafficking
pathwa ys to the lysosome were being utilized by wild-
type and mutant βAPP.
Discussion
In the present study, we demonstrate that endogenous
APP is enriched in neuronal lysosomes as well as lyso-
somes of Cos7 and SN56 cells that were transfected to
overexpress fluorescently tagged APP constructs. In addi-
tion to its expected transit from the cell surface to the
early endosomal compartment, surface-labeled wild-type
APP transits to the lysosomal compartment within min-
utes and appears to redistribute from the cell surface to
LAMP1 vesicles that are found in close proximity to the
plasma membrane. Wild-type APP is transported to the
lysosome more rapidly than to either early or late endo-
somes. These observations suggest that APP is trafficked
to the lysosome via a mechanism that is distinct from that
utilized by the non-specific uptake of dextran. Unexpect-
edly, two APP mutations that cause increased Aβ peptide
accumulation and early onset AD exhibit profound differ-
ences in their intracellular trafficking to lysosomes when
compared to wild-type APP. Taken together, these experi-
ments suggest distinct trafficking pathways for APP tran-
sit from the cell surface to the lysosome.
Although APP has been studied extensively, this is the
first demonstration of rapid protein transport directly
from the plasma membrane to the lysosome. That APP is
highly enriched in lysosomes has been previously
observed [28,36-38]. APP has also been demonstrated to
move to lysosomes within 15 minutes [7] to 2 hours [10]
but these studies did not quantitate either internalization
or colocalization. The easy detection of APP in lysosomes
suggests that it has a functional role in this compartment,
as the half life of lysosomal substrate proteins is 8 minutes
and lysosomal substrate proteins are expected to be
detectable only at very low levels [39]. One possible paral-
lel might be found in the prion protein (PrP) which nor-
mally traffics through early endosomes, but when
pathologically misfolded appears to transit to the lyso-
some without being observed in early endosomal com-
partments [40,41].
Our data demonstrating enrichment of APP in lyso-
somes has several limitations. The quantitation method
used here is based on colocalization of the brightest pix-
els. It therefore is likely only useful for comparing colo-
calization amongst discreet compartments and does not
represent an attempt to account for all of the APP in a
cell. For example large amounts of APP in other compart-
Figure 7 APP is rapidly internalized to the lysosome in live Cos7 cells. Cos7 cells were transiently co-transfected with wild type full length FL-
APP-CFP (A) or βAPP-CFP (B) constructs along with the LAMP1-mRFP compartment marker construct. Individual cells were selected and fluorescently-
labeled anti-HA antibody was added to the media. Laser confocal images were then acquired at approximately 2 frames/min.
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ments (such as the ER or the plasma membrane) would
not be accounted for if they had a lower levels of fluores-
cence intensity. In addition, compartment marker pro-
teins are often present in other compartments; for
example, colocalization with LAMP1 might also include
a u t o p h a g o s o m e s ,  w h i c h  h a v e  a l s o  b e e n  i d e n t i f i e d  a s  a
likely site of APP processing [42,43]. This study also spe-
cifically ignores possible cleavage events in biosynthetic
compartments as β- or γ-cleavage of the construct before
transport to the cell surface would remove the HA tag
and render these proteins invisible to our cell surface
labeling technique.
The appearance of APP in the lysosome before it
appears in the early endosomes suggests that wt-βAPP
can transit directly to the lysosome from the cell surface,
bypassing the early and late endosomal compartments. In
contrast both London and Swedish βAPP appear to be
excluded from this pathway and transit to the lysosome
with kinetics suggesting that they transit first through
early endosomes and then through late endosomes. This
might account for the fact that we observe less steady-
state localization of both London and Swedish APP in lys-
osomes. Furthermore, the decreased abundance of APP-
London in the late endosome, coupled with its accumula-
tion in early endosomes, is consistent with the relative
retention of APP-London in the early endosome. Inter-
estingly, Swedish APP is delivered to the late endosome at
a faster rate than either wild-type or London mutant APP
and yet at steady state there is no apparent difference in
the amount of London or wild-type APP in the Rab9 pos-
itive late endosome. This suggests that effective proteoly-
sis of APP-Swedish, which is expected to be cleaved by
BACE with much higher efficiency than APP-wt [22],
may occur as the protein transits from the late endosome
to the lysosome. Although this work does not rule out the
possibility that some APP might be cleaved by secretases
in biosynthetic compartments, it does demonstrate that
uncleaved APP (including APP-Swedish) is clearly pres-
ent on the cell surface. This data also suggests the pres-
ence of a novel and highly specific sorting system for APP
at the cell surface and a novel pathway from the cell sur-
face directly to the lysosome.
A model to account for the phenomena observed here
is that APP might transit to the lysosome by 2 distinct
pathways, the classical expected pathway through the
early and then late endosomes which has been previously
Figure 8 APP internalization into the endosomal/lysosomal system in SN56 cells. A. Representative images of the uptake of anti-HA antibody 
or fluorescent dextran (green) to lysosomes labeled with LAMP1-mRFP (red). B. Internalization of surface labeled APP was quantitated by determining 
the co-localization of the brightest 2% of pixels with fluorescent-tagged compartment marker proteins. Each point represents the Mean ± SEM for at 
least 3 independent experiments examining 4 representative cells each. These means were compared statistically using and ANOVA at each time 
point. * indicates statistical significance between LAMP1 and all other markers (P < 0.05). ** indicates Rab5 is statistically difference from Rab9 (P < 0.05).
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described [7], and another directly from the cell surface
to the lysosome either through an intermediate transport
v e s i c l e ,  o r  b y  d i r e c t  f u s i o n  a n d  r e c o v e ry  o f  l y s o s o m e s
with the plasma membrane. In this model, APP sorting
would occur at the cell surface, and APP bearing Swedish
and London mutations would be preferentially sorted
through the endosomal pathway. There is now good evi-
dence that different cell surface receptors can be directed
into distinct clathrin-coated pits based upon binding
domains in their intracellular C-terminus [44,45]. This
cell surface sorting system has been demonstrated to
direct proteins to at least 2 distinct types of endosomes,
with some cargo transported to slowly moving, slowly
maturing rab5-labeled endosomes, and some cargo
sorted to a rapidly maturing Rab7 labeled compartment
[46]. Because Rab7 can label both endosomes and lyso-
somes, this study might also be documenting direct lyso-
somal transport.
There is no simple explanation for how mutations in
the extracellular or transmembrane domain of APP might
alter its trafficking. Although proteins involved in APP
trafficking typically bind the cytoplasmic C-terminus of
Figure 9 Internalization of APP mutants into the endosomal/lysosomal system in SN56 cells. SN56 cells were cotransfected with the indicated 
βAPP and fluorescent-tagged compartment marker protein constructs as indicated. Cells were then surface labeled with AlexaFluor 647-labeled anti-
HA antibody on ice for 30 min and were then allowed to internalize this antibody at 37°C for the time indicated, fixed and imaged. For each time point, 
the colocalization of the brightest 2% of the anti-HA signal and the compartment marker was quantified (as in Figure 3). A. Internalization of surface-
labeled APP into the Rab5 compartment (early endosome). * indicates statistically significant difference between the βAPP-SW and βAPP-Lon mutants 
and all other markers (P < 0.05). ** indicates statistically significant difference between βAPP-Lon, βAPP-wt, and dextran (P < 0.05). *** indicates statis-
tically significant difference between βAPP-Lon, βAPP-SW, and βAPP-wt (P < 0.05). B. Internalization of surface-labeled βAPP (wt and mutant) into the 
Rab9 compartment (late endosome). * indicates statistically significant difference between APP-SW and all other markers. C. Internalization of surface-
labeled βAPP (wt and mutant) into the LAMP1 compartments. These means were compared statistically by ANOVA at each time point. * indicates 
statistically significant difference between APP-wt and all other markers (P < 0.05). ** indicates statistically significant difference between βAPP-SW 
and βAPP-wt from βAPP-Lon and dextran (P < 0.05).
β
β
βLorenzen et al. Molecular Brain 2010, 3:11
http://www.molecularbrain.com/content/3/1/11
Page 10 of 13
APP (reviewed in [47]), there are poorly defined signals in
the luminal domain of APP [23,29,48] and deletions of
the extracellular juxtamembrane segment of APP have
been shown to disrupt APP sorting [49], suggesting that a
trafficking mechanism exists which recognizes changes in
the extracellular domain of APP. One possible trafficking
regulator might be the γ-secretase complex itself (either
through presenilin or nicastrin), which can interact with
APP in the transmembrane and extracellular domain [50]
and only cleaves APP after a β-cleavage has occurred
[50,51]. This idea is supported by fact that mutations in
PS1 (D385N) that block γ-secretase activity or pharma-
cological inhibition of γ-secretase activity also block APP
internalization [52].
The pathways by which APP transits the endosomal/
lysosomal system may have implications for Aβ produc-
tion. For example, it is possible that the type of proteoly-
sis that APP undergoes may be related to the mechanism
by which the protein is being mobilized to the lysosome.
Thus, endocytosis through the early and late endosome
may lead to more efficient APP cleavage by secretases to
produce Aβ while rapid transport to lysosomes might
lead to degradation by lysosomal proteases. Because the
aggregation of Aβ is also favored by low pH as well as by
the intrinsic composition of the lysosomal membrane
[53,54], the route of delivery to the lysosome might also
affect amyloid formation.
Conclusions
Although many authors have implicated the lysosome in
the pathophysiology of Alzheimer's disease, lysosomes
are typically viewed as downstream sites in the trafficking
of APP and the production and clearance Aβ. Here we
demonstrate that APP is enriched in the lysosome in neu-
ronal cells compared to other endosomal compartments
and is rapidly and directly trafficked to the lysosomal
compartment. This rapid and specific transport event
potentially brings together APP, secretase enzymes, and
the conditions, which could either degrade beta amyloid
or nucleate its formation into fibrils. This suggests that
the endosomal/lysosomal system could play a central role
in the pathophysiology of Alzheimer's disease.
Methods
Antibodies and Reagents
Cos7 cells were obtained from Dr. Stephen Ferguson.
SN56 cells were obtained from Dr. Jane Rylett [30-32].
Serum for cell culture was purchased from Hyclone and
cell culture media and reagents were purchased from
Invitrogen. Antibodies used in this study were: rabbit
anti-APP-C-terminal (Sigma), monoclonal mouse anti-
LAMP1 (A3H4) and rat anti-LAMP1 (1D4B) (Develop-
mental Studies Hybridoma Bank), monoclonal anti-Rab5
(BD Biosciences), monoclonal anti-Rab9 (Affinity Biore-
agents), and monoclonal anti-HA antibody (12CA5)
(Roche Applied Science). Fluorescently-labeled second-
ary antibodies, AlexaFluor 488 goat anti-rabbit and Alex-
aFluor 633 donkey anti-mouse were purchased from
Invitrogen.
DNA Constructs
A cDNA encoding APP 750-YFP was a generous gift of
Dr. Bradley Hyman. HA-labeled APP constructs were
then generated by PCR, first cloning sequence encoding
the 17 amino acid signal sequence of APP as well as the L-
E residues required for signal peptide cleavage [55] with a
forward primer engineered to add an Nhe1 site and a
reverse primer encoding the HA sequence and appending
an Mlu1 site. The remainder of the cDNA was cloned
using PCR primers to place Mlu1 at the 3-prime end and
a Sal1 site at the 5-prime end. These 2 products were then
ligated into pEYFP-N1 or pECFP-N1 vectors (Clontech).
To reduce the possibility of cleavage of APP by a non-
secretase enzyme, we generated a shorter constructs
using a forward APP primer which would amplify the
sequence coding for the C-terminal 112 amino acids (12
amino acids upstream of the β-cleavage site) and append
a short 14 amino acid spacer and an Mlu1 site. This con-
struct is referred to as 'βAPP'. Constructs similar to βAPP
have been demonstrated to undergo both beta- and
gamma-cleavage [56]. We engineered London and Swed-
ish mutations into these constructs using PCR (Figure 1).
LAMP1-YFP was a generous gift from Dr. Walter
Mothes and recloned to use mRFP. Cox8-mRFP was a gift
from Dr. Mark Huttemann. Plasmids containing mCherry
were a gift from Dr. Roger Tsien. Rab9-YFP was obtained
from Dr. Susanne Pfeffer and re-cloned to use mCherry.
Cell Culture and transfection
SN56 cells and COS7 cells were grown in Dulbecco's
minimal Eagle's medium (DMEM), respectively supple-
mented with 5% (v/v) and 10% (v/v) heat-inactivated fetal
bovine serum (Hyclone) respectively, and 100 μg/ml pen-
icillin/streptomycin (Invitrogen). Cells were seeded at a
density of 2.5 × 106 cells/100-mm dish (Falcon). Cells
were transiently transfected using Lipofectamine follow-
ing manufacturer's instructions (Invitrogen). Following
transfection (18 h), the cells were pooled and reseeded
into 35-mm glass-bottomed culture dishes (MatTek) for
confocal studies. SN56 cells were grown as above, but
were differentiated 24 hours before imaging by the addi-
tion of 1 mM dibutyryl cyclic AMP (dbcAMP; Sigma) and
changed to serum free medium [30-32].
Primary prefrontal cortical neurons were prepared
from E18 mouse embryos as described previously [57],
then were seeded in poly-L-ornithine coated plates and
maintained in Neurobasal medium supplemented with
1× B27 and 0.8× N2 supplements, 2 mM glutamax and 50Lorenzen et al. Molecular Brain 2010, 3:11
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U/ml penicillin/streptomycin (Invitrogen). They were
kept at 37°C in a humidified atmosphere containing 5%
CO2. One third to one half of the volume of neurobasal
media was replenished every 3 days. After a growth
period of 8-15 days, neurons were processed for immun-
ofluorescence. The University of Western Ontario Ani-
mal Care Committee approved all animal protocols.
Immunocytochemistry
Cells were washed twice in Hanks' balanced salt solution
(HBSS; 1.2 mM KH2PO4, 5 mM NaHCO3, 20 mM
HEPES, 11 mM glucose, 116 mM NaCl, 4.7 mM KCl, 1.2
mM MgSO4, 2.5 mM CaCl2, pH 7.4) and fixed for 15 min.
in fresh methanol-free 4% paraformaldehyde (Electron
Microscopy Supply) in PBS. Cells were permeablized
with 0.02% Triton in PBS for 10 min and blocked with 3%
BSA in PBS for 1 h. Cells were incubated with primary
antibody for 1 hour, washed in PBS twice, incubated with
secondary antibody for 1 h. After 2 washes with PBS, cells
were stained with Hoechst nuclear stain (Sigma) in PBS
for 5 min at room temperature and mounted on slides
with ImmuMount (Fisher)
Confocal Microscopy
Imaging was performed on a Zeiss LSM-510 META laser-
scanning microscope using a Zeiss 63× 1.4 numerical
aperture oil immersion lens. The optical section thick-
ness was typically 1 micron. AlexaFluor 488, EGFP and
YFP fluorescence was visualized using a 488 nm excita-
tion laser and a 500-530-nm emission filter set. Alex-
aFluor 547 and mRFP fluorescence was imaged using a
543 nm excitation laser and BP 565-615 filter set. ECFP
fluorescence was imaged using 458 nm laser excitation
source and a BP 475-525 filter set. AlexaFluor 647 fluo-
rescence was imaged using 633 nm excitation laser, and a
LP 650 filter. Hoechst signal was collected using a Cha-
meleon Multiphoton laser set at 750 nm excitation, and a
390-465 emission filter set.
Cell Surface labeling
Anti-HA antibody was labeled with AlexaFluor 647 using
a Zenon labeling kit (Invitrogen) following manufac-
turer's directions. Live cell imaging was performed in
HBSS at 37°C on a BC200 microscope stage warmer with
a Bionomic BC100 controller from (20/20 Technologies).
Cells normal morphology and strong expression of APP
and compartment markers were identified for imaging. In
live cell imaging experiments, and images were typically
taken at 1-2 frames/minute.
For fixed time-course studies, freshly prepared conju-
gate (10 μg of antibody/ml) was incubated with cells in
DMEM on ice for 30 minutes. Conjugate was removed
and the cells are washed in cold PBS. Pre-warmed media
was then added and cells were incubated at 37°C for the
times indicated prior to fixation with 4% paraformalde-
hyde. Cells were chosen which had strong expression of
both the APP and the compartment marker constructs,
but had normal morphology and no inclusions. βAPP
time courses were performed at least 3 times, with at
least 4 representative cells imaged at each time point.
For dextran uptake time courses, AlexaFluor 647-
labeled 10 kDa Dextran (Invitrogen) was added to media
at 100 μg/ml and cells were incubated for the indicated
length of time. Media was then aspirated, cells were
washed in ice-cold PBS and fixed 4% paraformaldehyde.
Colocalization Analysis
Colocalization analysis was performed on confocal opti-
cal sections using Imaris 6.1.5 with Imaris Colocalization
module (Biplane) running on an Apple Mac Pro to exam-
ine the colocalization of the brightest 2% of pixels in each
channel. This allows us to set threshold for colocalization
in an unbiased manner using the intrinsic properties of
the image, eliminating confounding problems caused by
variations in cell-to-cell expression and image brightness/
exposure thus allowing direct comparison between
experiments. Graphing and statistical analysis was per-
formed using Prism GraphPad 5.0b using one-way
ANOVA with Tukey post-test.
Additional material
Additional file 1 Image stack demonstrating APP preferentially local-
ized in the lysosome a neuronal SN56 cell. SN56 cells were transiently 
co-transfected with βAPP-CFP (green) and LAMP1-mRFP (red). Image stack 
was acquired on a Zeiss LSM510 confocal microscope. The first segment 
shows βAPP-CFP in green. The second segment of the video shows LAMP1-
mrfp overlaid in red. In the third segment, a colocalization channel, show-
ing the colocalization of the brightest 2% of red and green pixels is overlaid 
in white. QuickTime video was generated using Imaris 6.1.5 software to per-
form volume rendering and animation.
Additional file 2 Image stack of an immunostained mouse neuron 
demonstrating APP in the lysosome. Cultured mouse neurons were fixed 
and immunolabeled with anti-APP (green) and anti-LAMP1 antibodies (red) 
and Hoechst nuclear stain (blue). Image stack was acquired on a Zeiss 
LSM510 confocal microscope. The first segment shows βAPP-CFP in green. 
The second segment of the video shows LAMP1-mRFP overlaid in red. In 
the third segment, a channel showing the colocalization of the brightest 
2% of red and green pixels is overlaid in white. QuickTime video was gener-
ated using Imaris 6.1.5 software to perform volume rendering and anima-
tion.
Additional file 3 Movie demonstrating the internalization of FL-APP 
to the lysosome in a Cos7 cell. Cos7 cells were transiently transfected with 
FLAPP-CFP (not shown) and LAMP1-mRFP (red). Fluorescent-labelled anti-
HA antibody was added to the media, and a cell was chosen which had 
good expression of transfected plasmids. Images were acquired using laser-
scanning confocal microscopy at approximately 2 frames/min. QuickTime 
video was generated using Imaris 6.1.5 software.
Additional file 4 Movie demonstrating the internalization of βAPP to 
the lysosome in a Cos7 cell. Cos7 cells were transiently transfected with 
βAPP-CFP (not shown) and LAMP1-mRFP (red). Fluorescent-labelled anti-
HA antibody was added to the media, and a cell was chosen which had 
good expression. Images were acquired using laser-scanning confocal 
microscopy at approximately 2 frames/min. QuickTime video was gener-
ated using Imaris 6.1.5 software.Lorenzen et al. Molecular Brain 2010, 3:11
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